New-Age Vaccine Adjuvants: Friend or Foe? - A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity - BioPharm

ADVERTISEMENT

New-Age Vaccine Adjuvants: Friend or Foe?
A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity


BioPharm International


36. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86–91.

37. McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry JA, et al. A phase 1 trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 2000;18:1166–1177.

38. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001;19:2666–2672.

39. Byars NE, Allison AC. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 1987;5:223–228.

40. Edelman R. Adjuvants for the future. In: Levine M, Woodrow J, Kaper J, Cobon D, editors. New generation vaccines. New York: Marcel Dekker Inc. 1997;p. 173–192

41. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995;6:277–296.

42. Akira, S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 124:783–801.

43. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17:3094–3101.

44. Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999;15:573–576.

45. Influenza vaccine with squalene adjuvant: new preparation. No better than available products. Prescrire Int 2004;13:206–208.

46. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996;174:1168–1175.

47. Wright T, Tong M, Hsu H. Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis B. In: American Association for the Study of Liver Diseases 50th Annual Meeting; Dallas, Texas 1999; Abstract 1042.

48. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000;156:2057–2065.

49. Freund J. The mode of action of immunologic adjuvants. Bibl Tuberc 1956;130–148.

50. De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000;12:807–815.

51. Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 1992;143:483–488; discussion 573–484.

52. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495–524.

53. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617–1624.

54. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879–2883.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis and GSK Trade Assets
April 22, 2014
Lilly to Acquire Novartis Animal Health
April 22, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here